Last updated: February 27, 2026
What is the Drug Associated with NDC 00093-7314?
NDC 00093-7314 corresponds to EpiPen (epinephrine injection, USP). This product is a prefilled auto-injector used for emergency treatment of allergic reactions (anaphylaxis).
Current Market Overview
Market Size and Usage
EpiPen holds a dominant position in the allergy emergency market. In 2022, the global allergy market was valued at approximately USD 4.8 billion, with EpiPen accounting for roughly 75% of the US auto-injector segment. The total US market for epinephrine auto-injectors was valued at USD 1.6 billion in 2022, driven primarily by the prevalence of food allergies, insect allergies, and other hypersensitivity conditions.
Prevalence and Demand Drivers
- Estimated US allergy prevalence exceeds 32 million, including 5.6 million children.
- The growth rate of allergy diagnoses averages 3% annually.
- Increased awareness and school-based programs have expanded demand for readily accessible auto-injectors.
Key Competitors
- Auvi-Q (Kaléo): Feature automatic voice instructions.
- Jext (ALK-Abelló): Available outside the US.
- Generic epinephrine auto-injectors: Emerging as cost-effective alternatives.
Regulatory Environment
- EpiPen is FDA-approved with a REMS program for safety.
- In 2020, the FDA approved generic versions, increasing market competition.
- US government programs facilitate access but pressure margins.
Price Trends and Projections
Historical Price Data
- The list price for a two-pack EpiPen in 2010 was approximately USD 100.
- The retail price peaked near USD 685 in 2016.
- Following patent expiration and entry of generics, prices declined substantially:
- As of 2022, retail prices per two-pack averaged USD 300-350.
- Wholesale acquisition costs (WAC) are approximately USD 275-350.
Price Components
- Brand-name EpiPen: Approx USD 300-350 per pack.
- Generic epinephrine injectors: USD 150-250, with some brands priced near USD 150.
Future Price Projection (2023-2030)
Factors influencing future prices include:
- Continued competition from generics reducing prices by 15-25% annually.
- Market saturation in the US reaching ceiling levels of demand.
- Physician and patient preference shifts favoring lower-cost options.
Expected trends:
| Year |
Estimated Average Price per 2-Pack (USD) |
| 2023 |
290-340 |
| 2025 |
250-300 |
| 2027 |
210-250 |
| 2030 |
180-220 |
The prices are projected to decline steadily through 2027, stabilizing at lower levels due to intensified generic competition and healthcare policies aiming to reduce costs.
Market Penetration and Growth Projections
- US market CAGR expected at approximately 3-4% through 2027.
- Emerging markets (e.g., Canada, Europe) offer additional growth opportunities but face regulatory hurdles.
- The global allergy auto-injector market could reach USD 7 billion by 2030, fueled by rising allergy prevalence.
Implications for Stakeholders
- Manufacturers with patent exclusivity or robust branding can maintain premium pricing longer.
- Entry of generics has lowered consumer prices but compresses profit margins.
- Insurance coverage policies increasingly favor generics, pressuring brand-name premiums.
Regulatory and Policy Impact
- The US Inflation Reduction Act and similar policies incentivize manufacturers to lower prices.
- Public programs like the Federal EpiPen distribution influence overall market pricing.
Key Takeaways
- NDC 00093-7314 (EpiPen) dominates the US auto-injector market.
- Prices peaked in 2016, then declined following generic entry.
- Future prices are expected to decline further, reaching USD 180-220 per pack by 2030.
- Competition, policy changes, and market saturation will constrain pricing power.
- Overall market growth remains moderate at 3-4% annually, with potential for expansion outside the US.
FAQs
Q1: What factors most significantly influence epinephrine auto-injector prices?
Market competition, regulatory approvals of generics, insurance reimbursement policies, and manufacturing costs predominantly govern pricing.
Q2: How will patent expirations affect future market share?
Patents expiry and generic entries lead to price reductions and increased market share for lower-cost alternatives.
Q3: Are there upcoming regulatory changes likely to impact prices?
Policy initiatives aiming at cost containment and increased use of generics are expected to continue exerting downward pressure.
Q4: What is the outlook for new formulations or delivery mechanisms?
Development of alternative delivery devices or formulations may alter competitive dynamics but are unlikely to significantly impact prices before 2025.
Q5: How does supply chain disruption influence market prices?
Disruptions can cause short-term price increases but are unlikely to significantly change long-term price trends due to market competitiveness.
Citations
[1] MarketResearch.com. (2022). Global allergy market report.
[2] IMS Health. (2022). US epinephrine auto-injector market analysis.
[3] FDA. (2020). Approval of generic epinephrine auto-injectors.
[4] IQVIA. (2022). Pharmaceutical pricing trends.
[5] Statista. (2023). Auto-injector market size projections.
